Fatty liver disease (MASLD/MASH) trials in Denmark

In Denmark 9 Also abroad 367

9 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Where
Copenhagen Nv, Hvidovre
Age
18 years and over
People
205 worldwide
Run by
Akero Therapeutics Inc.
See details and how to join2024-512895-36-00 · EU 2024-512895-36-00
Phase 3Taking people
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Where
Hvidovre
Age
18 years to 80 years
People
2,150 worldwide
Run by
Akero Therapeutics, Inc
See details and how to joinNCT06528314
No phaseTaking people
Increased Risk of Non-alcoholic Fatty Liver Disease in Low Birth Weight Individuals
Where
Herlev
Age
34 years to 49 years
People
300
Run by
Steno Diabetes Center Copenhagen
See details and how to joinNCT05890365
No phaseTaking people
Identification of Liver Fibrosis Biomarkers
Where
Copenhagen
Age
18 years to 75 years
People
575 worldwide
Run by
Roche Diagnostics GmbH
See details and how to joinNCT06819917
No phaseTaking people
Non-alcoholic Fatty Liver Disease in Low Birth Weight Individuals
Where
Aarhus, Herlev
Age
35 years to 40 years
People
8
Run by
Steno Diabetes Center Copenhagen
See details and how to joinNCT05842850
No phaseTaking people
Glucagon Resistance in Patients With MASLD and T2DM
Where
Aarhus
Age
30 years to 70 years
People
24
Run by
University of Aarhus
See details and how to joinNCT07246421
No phaseTaking people
Prognostic Significance of Fatty Liver Disease in Bariatric Patients
Where
Esbjerg
Age
18 years and over
People
1,200
Run by
Esbjerg Hospital - University Hospital of Southern Denmark
See details and how to joinNCT03535142
No phaseTaking people
Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers
Where
Odense
Age
30 years to 75 years
People
6,500
Run by
Maja Thiele
See details and how to joinNCT03308916
No phaseTaking people
An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis
Where
Hvidovre
Age
18 years and over
People
335
Run by
University of Copenhagen
See details and how to joinNCT05335603